Depacon

Migraine, Acute Coryza, Behcet Syndrome + 4 more
Treatment
20 Active Studies for Depacon

What is Depacon

Valproic acidThe Generic name of this drug
Treatment SummaryValproic acid, or valproate, is a medication that was first used as an organic solvent in industry and pharmaceuticals in 1881. In 1963, it was discovered to have anticonvulsant properties and was approved by the FDA in 1978 under the trade name Depakene. Today, valproic acid is used to treat seizures, mania, migraines, and may even have neuroprotective and anti-cancer effects. It is currently being studied in clinical trials to investigate its potential as an anti-proliferative drug for cancer treatment.
Depakeneis the brand name
image of different drug pills on a surface
Depacon Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Depakene
Valproic acid
1978
481

Effectiveness

How Depacon Affects PatientsValproate can help reduce the number of complex partial seizures and migraine headaches, and is also thought to aid in the control of bipolar mania. It's not fully understood how it works, but it is believed to help by increasing the amount of inhibition in the brain. Valproate has been found to also help protect the brain from damage and neural degeneration, but it can also be toxic to the liver and cause birth defects. A small study suggested that it might help with HIV clearance when taken with other treatments, but a larger study did not find any significant effect. The FDA warns that HIV may become reactivated when taking Val
How Depacon works in the bodyValproate works in a variety of ways to help treat epilepsy, migraine headaches, and bipolar disorder. It reduces the amount of GABA being broken down, which is an inhibitory neurotransmitter. This increase in GABA activity results in increased inhibition in the brain. Valproate also affects pathways related to cell growth and survival, as well as fatty acid metabolism, which can reduce inflammation. Finally, it works as a direct inhibitor of histone deactylase, which can lead to changes in gene expression. These effects combined work to reduce seizures, decrease inflammation, and improve symptoms associated with bipolar disorder.

When to interrupt dosage

The prescribed dosage of Depacon is contingent upon the affirmed condition, including Seizures, Seizure, Absence and Complex Partial Seizures. The amount of dosage can be found in the table below, dependent upon the technique of delivery (e.g. Injection, solution - Intravenous or Capsule, delayed release).
Condition
Dosage
Administration
Mental Depression
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Seizures
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Migraine
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Acute Coryza
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Behcet Syndrome
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release
Epilepsy
, 250.0 mg, 125.0 mg, 500.0 mg, 250.0 mg/mL, 100.0 mg/mL, 50.0 mg/mL, 500.0 mg/mL
, Oral, Tablet, extended release, Tablet, extended release - Oral, Capsule - Oral, Capsule, Solution, Solution - Oral, Tablet, delayed release, Tablet, delayed release - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, liquid filled, Capsule, liquid filled - Oral, Tablet, delayed release particles, Tablet, delayed release particles - Oral, Tablet, Intravenous, Injection, solution, Injection, solution - Intravenous, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, delayed release, Capsule, delayed release - Oral, Injection - Intravenous, Injection, Liquid - Intravenous, Liquid, Capsule, Delayed Release - Oral, Tablet - Oral, Syrup, Syrup - Oral, Capsule, Delayed Release

Warnings

Depacon Contraindications
Condition
Risk Level
Notes
Mitochondrial Diseases
Do Not Combine
Liver Failure
Do Not Combine
Disease
Do Not Combine
Liver Diseases
Do Not Combine
Enzymes
Do Not Combine
There are 20 known major drug interactions with Depacon.
Common Depacon Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Valproic acid.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Valproic acid.
Aminophylline
Major
The metabolism of Aminophylline can be decreased when combined with Valproic acid.
Amiodarone
Major
The metabolism of Amiodarone can be decreased when combined with Valproic acid.
Depacon Toxicity & Overdose RiskThe amount of Valproate that is toxic to mice is 1098mg/kg and 670mg/kg for rats. Symptoms of an overdose can include drowsiness, abnormal heart rhythm, deep unconsciousness, high sodium levels, and in some cases death. Hemodialysis can be used to remove the drug from the body. Valproate use during pregnancy can increase the risk of birth defects such as neural tube defects, facial defects, and other physical abnormalities. It can also lead to lower IQ and autism spectrum disorder in children. Valproate can be found in breast milk and has been linked to male infertility. It should
image of a doctor in a lab doing drug, clinical research

Depacon Novel Uses: Which Conditions Have a Clinical Trial Featuring Depacon?

65 active clinical trials are being conducted to examine the possibility of deploying Depacon as a potential therapy for Migraine, Complex Partial Seizures and Acute Coryza.
Condition
Clinical Trials
Trial Phases
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Seizures
0 Actively Recruiting
Seizures
0 Actively Recruiting
Acute Coryza
1 Actively Recruiting
Not Applicable
Behcet Syndrome
1 Actively Recruiting
Not Applicable
Epilepsy
0 Actively Recruiting
Mental Depression
2 Actively Recruiting
Phase 2, Not Applicable

Patient Q&A Section about depacon

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Depakote and Depacon the same?

"Depacon is a drug that is very similar to Depakene and Depakote. It is often referred to as valproate. In the United Kingdom, it is marketed by Sanofi under the brand Epilim."

Answered by AI

Is Depacon valproic acid?

"Valproate products are sometimes used to treat conditions other than the ones they are approved for. These products include valproate sodium, divalproex sodium, valproic acid, and their generics."

Answered by AI

What is Depacon migraine?

"Depacon is used more frequently in patients who have epilepsy to achieve rapid titration of medication or who cannot take their medication orally. Depacon has the same indications as oral valproic acid, such as migraine prophylaxis, generalized and partial seizures, and bipolar illness."

Answered by AI

What is Depacon used for?

"Depacon is an anti-seizure medication that can be used by itself or along with other seizure medications to treat complex partial seizures, which are seizures that can happen alone or with other types of seizures."

Answered by AI

Clinical Trials for Depacon

Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Image of Mount Sinai Hospital in New York, United States.

Rimegepant + Zavegepant for Migraine

18+
All Sexes
New York, NY
This study evaluates the effectiveness of rimegepant 75 mg orally disintegrating tablet (ODT) single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments during Emergency Department (ED) encounters. Although these two calcitonin gene-related peptide receptors (CGRP) receptor antagonists are FDA-approved for the indication of acute migraine treatment, past studies have been limited to the outpatient setting. If these medications are effective in the Emergency Department, their delivery methods alone may have advantages over intravenous medications commonly used for acute migraine in EDs, including quicker time to treatment delivery, faster pain relief, and reduced ED length of stay. This investigation is a pilot study to examine rimegepant and zavegepant in an ED, to gain insight on effectiveness in this setting. This study will administer rimegepant 75 mg ODT single-dose or zavegepant 10 mg nasal spray single-dose as acute migraine treatments to 100 patients in the Emergency Department. It is a single center, open-label, non-controlled 2-group clinical trial (allocated 1:1 to rimegepant or zavegepant via pseudo-random assignment). The study will enroll adults in the ED meeting ICHD-3 criteria for migraine or probable migraine, with or without aura.
Phase 4
Recruiting
Mount Sinai HospitalJonathan SchimmelPfizer
Have you considered Depacon clinical trials? We made a collection of clinical trials featuring Depacon, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota in Minneapolis, United States.

Visual Adaptation for Visual Snow

18 - 60
All Sexes
Minneapolis, MN
The goal of this study is to learn more about the brain pathways and activity involved in creating Visual Snow Syndrome (VSS). The main questions it aims to answer are: * Does VSS arise from spontaneous activity in brain pathways? * Where in the brain does the activity contributing to VSS arise? * How does brain activity contribute to VSS? Participants will: 1. Undergo assessments and questionnaires to understand visual and mental symptoms, cognitive, and sensory function. 2. Make visual judgements based on images presented to them both inside and outside a magnetic resonance imaging (MRI) machine. 3. Undergo scanning of their brain while inside of an MRI machine.
Recruiting
Paid Trial
University of MinnesotaMichael-Paul Schallmo, Ph.D.
Image of HCA Florida north florida Hospital in Gainesville, United States.

Bupivacaine Injection for Headache

18+
All Sexes
Gainesville, FL
Headache is a frequent chief complaint among patients presenting to the Emergency Department (ED), accounting for 2.1 million visits annually in the United States. Often, individuals resort to ED care only after over-the-counter or home remedies have failed, leading to the predominant use of intravenous (IV) medications in the ED, including NSAIDs, triptans, neuroleptics, antiepileptics, and dopaminergic antagonists. Unfortunately, these pharmacologic treatments frequently induce side effects such as cognitive impairment, extrapyramidal reactions, and the potential for medication dependency. In the ED, patients frequently require concurrent administration of multiple systemic medications to achieve satisfactory pain relief, thereby elevating the risk associated with medication use. Despite these medication regimens, a significant portion of patients continue to experience inadequate pain relief. Consequently, the search for an optimal headache therapy-characterized by rapid and effective pain relief, long lasting results, minimal side effects, and allows for rapid ED patient turnover-continues to be a popular area of research in emergency medicine. The investigators plan to evaluate the use of 0.5% bupivacaine cervical IM injection at the c6-7 location for the treatment of non traumatic headaches using a non-inferiority design, randomized, prospective, open-label, controlled trial comparing it to physicians choice of intravenous medications in treatment of headache in the Emergency Department at North Florida Hospital.
Phase 3
Waitlist Available
HCA Florida north florida HospitalRobyn Hoelle, MD
Have you considered Depacon clinical trials? We made a collection of clinical trials featuring Depacon, we think they might fit your search criteria.Go to Trials
Image of Brigham and Women's Hospital in Boston, United States.

Cocoa Extract for Migraine

18+
All Sexes
Boston, MA
The goal of this clinical trial is to assess the feasibility of recruitment and adherence to a high-dose cocoa extract supplement in individuals diagnosed with episodic migraine. The main questions it aims to answer are: * Will we be able to enroll 114 participants during the recruitment period? * Will participants take study pills daily during the pill-taking period? Researchers will compare two doses of cocoa extract to placebo to determine the acceptability of higher doses of cocoa extract supplementation in this patient population. Participants will be asked to: * Provide two urine samples * Complete daily questionnaires * Take four study pills a day for 12 weeks
Recruiting
Dietary Supplement
Brigham and Women's HospitalPamela M Rist, ScD
Have you considered Depacon clinical trials? We made a collection of clinical trials featuring Depacon, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security